- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Use of low-dose atropine eyedrops may not arrest myopia progression
China: In a study published in Graefe's Archive for Clinical and Experimental Ophthalmology, entitled "Effect of low-dose atropine eyedrops on pupil metrics: results after half a year of treatment and cessation" by Wei-Ling Bai and colleagues, researchers have found that pupil size and the constriction ratio return to pre-atropine levels after cessation. A once-nightly dose of 0.01% atropine eyedrops increased pupil diameter and decreased constriction ratio but did not influence the Pupillary Light Reflex or PLR.
Low-concentration atropine eyedrops are used for myopia treatment. The effects for controlling myopia development could be better with a higher concentration of atropine eyedrops but with a risk of adverse effects and a more obvious rebound after drug cessation. However, there needs to be more data on ideal atropine concentration.
Researchers evaluated the effect of low-dose atropine eyedrops on pupil metrics in mainland China's double-masked, placebo-controlled, and crossover trial.
In phase 1, subjects received 0.01% atropine or placebo once nightly. After one year, the atropine group switched to placebo (atropine-placebo group), and the placebo group switched to atropine (placebo-atropine group).
Researchers measured ocular parameters at the crossover time point (12th month) and the 18th month.
The results of the study are:
- One hundred five subjects completed the study.
- The atropine-placebo and placebo-atropine groups had 48 and 57 children, respectively.
- There was a decrease in the photopic pupil diameter (PD) and mesopic PD and an increase in constriction ratio (CR, %) than values at the crossover time point of the atropine-placebo group (after cessation).
- There was no difference in pupil metrics of the atropine-placebo group from the values at the crossover time point of the placebo-atropine group.
- There was an increase in the photopic PD, and the mesopic PD increased and decreased in the CR after six months of treatment, compared with values at the crossover time point of the placebo-atropine group.
- During 0.01% atropine treatment, pupil metrics and myopia progression had no association.
They concluded that Pupil metrics and the CR could return to pre-atropine levels following cessation. During treatment, Pupil metrics had no significant effect on myopia progression.
The study's limitations were the lack of baseline measurement of pupil metrics for the atropine-placebo group before atropine treatment, failure to measure the pupil metrics at the beginning of the first year and higher drop-out rate.
Further research is warranted for analysing different atropine concentrations and longer follow-ups in validating the specific long-term effects of atropine on pupil metrics.
Further reading:
Bai, WL., Gan, JH., Wei, S. et al. Effect of low-dose atropine eyedrops on pupil metrics: results after half a year of treatment and cessation. Graefes Arch Clin Exp Ophthalmol 261, 1177ā1186 (2023). https://doi.org/10.1007/s00417-022-05863-8
BDS, MDS in Periodontics and Implantology
Dr. Aditi Yadav is a BDS, MDS in Periodontics and Implantology. She has a clinical experience of 5 years as a laser dental surgeon. She also has a Diploma in clinical research and pharmacovigilance and is a Certified data scientist. She is currently working as a content developer in e-health services. Dr. Yadav has a keen interest in Medical Journalism and is actively involved in Medical Research writing.
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751